Fate Therapeutics (FATE) Misses Q1 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.38), $0.01 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen